Gilead Sciences, Inc. research snapshot
GILD AI stock analysis currently reads Gilead Sciences as a cash-generative biopharma company anchored by HIV treatment and prevention, supported by liver disease and oncology assets, but still exposed to patent, pricing, cell therapy, acquisition, and pipeline execution risk. At the July 8, 2026 data cutoff, GILD traded near $136.36 with a verified market value near $171.00 billion. This page uses source-backed data, scenario ranges, technical levels, and a rules-based trading strategy framework. It is informational research, not investment advice.
Current price
$136.36
Market cap
$171.00 billion verified market cap
AI score
70 / 100
Rating
High-cash-flow biopharma franchise with HIV strength and pipeline execution risk
Trend status
Mixed technical setup with near-term support above the 200-day trend line
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Gilead sells HIV, liver disease, oncology, and cell therapy medicines with a large recurring HIV base and strong free cash flow conversion. | High |
| Moat | The moat is strongest in HIV, where clinical evidence, prescriber trust, payer access, regulatory approvals, formulation know-how, and prevention scale support durable demand. | Medium-high |
| Management | Management should be judged by HIV lifecycle execution, Yeztugo commercialization, oncology returns, cell therapy stabilization, dividend coverage, debt management, and disciplined acquisitions. | Medium |
| Financial trend | FY2025 revenue rose 2% to $29.443 billion and net income reached $8.510 billion, while Q1 2026 revenue rose 4% to $7.0 billion and product sales rose 5% to $6.9 billion. | High |
| Valuation | At $136.36, audited math shows about 18.6x TTM EPS, 17.7x FY2025 free cash flow per share, 7.3x book value, and a dividend yield near 2.3%. | Medium-high |
| Technical trend | Financhill showed GILD above its 8-day, 20-day, and 50-day simple moving averages, slightly below one 200-day reference, and rated the stock Sell at a 47 score. | Medium |
| Risk level | Major risks are HIV patent and pricing pressure, Yeztugo uptake versus expectations, cell therapy competition, oncology trial risk, acquired IPR&D charges, and regulatory or payer changes. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and product data are detailed. Forecast confidence is medium because drug-specific events can reset earnings and multiples. | High data confidence |
| Investment certainty | Investment certainty is medium. GILD has high cash generation, but margin of safety depends on normalized EPS power after 2026 acquisition charges and on HIV franchise durability. | Medium |
GILD AI stock forecast
The GILD AI stock forecast uses scenario math around the $136.36 cutoff price and normalized EPS of $8.65, based on Gilead management commentary that acquisition and financing costs reduced 2026 non-GAAP EPS guidance by about $9.50. The audited three-year model produced valuation anchors near $185 in the bullish case, $142 in the base case, and $87 in the bearish case before dividends. These are scenario ranges, not guaranteed targets.
$175 to $190
More likely if Biktarvy and Descovy stay resilient, Yeztugo reaches large prevention adoption, Trodelvy and Livdelzi keep growing, cell therapy stabilizes, acquisitions add credible pipeline value, and investors pay about 18x normalized earnings.
$135 to $150
More likely if normalized EPS compounds at a low single-digit rate, HIV growth offsets Veklury and HCV declines, oncology improves gradually, and the market values Gilead near a mid-teens earnings multiple.
$80 to $95
More likely if HIV pricing or patent pressure arrives sooner than expected, Yeztugo expectations prove too high, cell therapy keeps declining, oncology trials disappoint, or acquired IPR&D spending fails to create durable growth.
GILD AI technical analysis
GILD AI technical analysis is mixed as of the July 8, 2026 cutoff. Financhill listed GILD near $129.61 on its July 5 update, above the 8-day, 20-day, and 50-day simple moving averages but slightly below one 200-day simple moving average, while assigning a Sell rating and score of 47. ChartMill listed support zones below the market and a resistance zone near $126.64 to $128.07 from its recent snapshot, so live quote confirmation matters.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $136.36 | StockAnalysis quote snapshot after the July 7, 2026 close used for market-cap and valuation math. |
| Near support | $127 to $130 | Financhill listed the 8-day SMA near $127.05, the 20-day SMA near $126.14, and the 50-day SMA near $129.54 on its July 5 technical snapshot. |
| Secondary support | $120 to $123 | ChartMill listed a support zone from $120.25 to $123.21 based on trend lines and moving averages. |
| Long-term trend reference | $128 to $130 | Financhill showed 200-day references around $128.33 to $130.01, which makes the long-term signal sensitive to source and timestamp. |
| Resistance | $157.29 | Financhill listed a 52-week high near $157.29, which is the major upside reference for a renewed breakout. |
| Momentum | Score 47 / 100, RSI 53.83 | Financhill rated GILD Sell at 47 even though several moving-average readings were positive, so the signal mix is not clean. |
| Volume | 9.8 million shares in the Financhill snapshot | Volume should be interpreted against earnings, FDA, patent, payer, and acquisition news because biopharma volume can spike around event risk. |
| Volatility | Event-sensitive large-cap biopharma volatility | Clinical updates, payer decisions, HIV prevention uptake, and acquisition accounting can matter more than normal chart patterns. |
| Invalidation | Close below $127, then below $120 | A break below the short moving-average zone would weaken the swing setup. A sustained break below the $120 to $123 zone would require a fuller thesis review. |
GILD AI trading strategy
The GILD AI trading strategy below is a rules-based framework for a mature biopharma stock with a large HIV cash engine, dividend support, event risk, and pipeline optionality. It is not personal advice and should be paired with live quotes, filings, FDA calendars, position sizing, and risk controls.
Watch for GILD to hold above the $127 to $130 moving-average zone and build toward the $157 52-week high with confirming volume and no negative HIV, payer, trial, or acquisition news.
A close below $127 should reduce swing confidence. A close below the $120 to $123 support zone should trigger a full review of the technical and fundamental setup.
If GILD pulls back toward the 200-day area without a new patent, pricing, clinical, or guidance problem, compare the reset price with normalized EPS power, free cash flow yield, dividend coverage, and the audited base scenario.
Do not average down through drug-specific bad news. HIV pricing, FDA, trial, and payer events can convert a technical pullback into a fundamental break.
Track Biktarvy, Descovy, Yeztugo, Trodelvy, Livdelzi, Yescarta, Tecartus, Veklury decline, product sales excluding Veklury, operating cash flow, debt repayments, dividend coverage, and acquired pipeline progress.
Lower confidence if EPS recovery depends mainly on multiple expansion, one-time adjustments, or acquisitions rather than durable product growth and cash generation.
Investment research summary
Gilead converts antiviral and oncology science, clinical evidence, regulatory approvals, payer access, and global commercial execution into recurring medicine revenue for serious diseases.
The moat is deepest in HIV, where product trust, regimen convenience, prevention leadership, reimbursement access, patents, manufacturing quality, and physician familiarity reinforce each other. It narrows when exclusivity weakens or rivals offer better efficacy, safety, dosing, or price.
The thesis fails if HIV growth slows before new products scale, if Yeztugo adoption falls short of expectations, if oncology and cell therapy assets disappoint, if pricing pressure compresses margins, or if acquisition spending dilutes owner earnings.
Management has protected a large HIV franchise, raised 2026 product sales guidance, repaid debt, paid dividends, and used acquisitions to rebuild the pipeline. The key test is whether these deals produce clinical and commercial returns above their cost.
Biopharma benefits from aging populations, longer chronic disease treatment, HIV prevention innovation, oncology advances, and rare disease demand. The industry also faces patent cliffs, Medicare and payer pressure, clinical binary risk, and policy scrutiny.
GILD is valued below high-growth biotech multiples but not as a distressed stock. Margin of safety depends on whether normalized earnings near the pre-acquisition guidance range remain durable after 2026 IPR&D charges.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GILD quote reference | $136.36 close on July 7, 2026 | StockAnalysis GILD balance sheet and quote snapshot | July 8, 2026 |
| Market capitalization verification | $171.00 billion, verified as $136.36 x about 1.254 billion shares | Pineify financial_rigor.py and StockAnalysis share data | July 8, 2026 |
| Shares outstanding | 1.24 billion shares outstanding | StockAnalysis GILD statistics | July 8, 2026 |
| FY2025 revenue | $29.443 billion, cross-validated against company filing and Macrotrends | Gilead 2025 Form 10-K and Macrotrends revenue table | July 8, 2026 |
| FY2025 net income and diluted EPS | $8.510 billion net income and $6.78 diluted EPS | Gilead 2025 Form 10-K | July 8, 2026 |
| FY2025 product sales mix | $28.9 billion product sales, including $20.8 billion HIV, $3.2 billion liver disease, $1.8 billion cell therapy, and $1.4 billion Trodelvy | Gilead FY2025 financial results release | July 8, 2026 |
| Q1 2026 revenue and EPS | $7.0 billion revenue, $6.9 billion product sales, $1.61 GAAP diluted EPS, and $2.03 non-GAAP diluted EPS | Gilead Q1 2026 financial results release | July 8, 2026 |
| Q1 2026 cash and marketable debt securities | $8.6 billion per company release, cross-checked at about $8.615 billion using StockAnalysis cash and marketable debt securities | Gilead Q1 2026 release and StockAnalysis balance sheet | July 8, 2026 |
| Total debt | $22.174 billion TTM total debt and net debt near $14.531 billion | StockAnalysis GILD balance sheet | July 8, 2026 |
| Free cash flow | $9.639 billion TTM free cash flow and $7.69 free cash flow per share | StockAnalysis GILD cash flow statement | July 8, 2026 |
| Technical snapshot | Financhill score 47, price $129.61, 8-day SMA $127.05, 20-day SMA $126.14, 50-day SMA $129.54, 200-day SMA $130.01 | Financhill GILD technical analysis | July 8, 2026 |
This GILD AI stock analysis is an informational research tool only. It is not investment advice, a solicitation, or a personalized recommendation. Forecast ranges are scenarios based on available data as of July 8, 2026 and can be wrong if clinical, regulatory, pricing, competitive, macro, or market multiple assumptions change.
